Esophageal Cancer Clinical Trials in Pittsburgh, Pennsylvania
11 studies are recruiting for esophageal cancer in Pittsburgh, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GE…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Research Site, Pittsburgh, Pennsylvania
- Locations
- 311 in total
- Run by
- AstraZeneca
-
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, and HER3-DXD plus ramucirumab versus ramucirumab plus paclitaxel for the treatment of participants …
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- UPMC Hillman Cancer Center-UPMC ( Site 8904), Pittsburgh, Pennsylvania
- Locations
- 46 in total
- Run by
- Merck Sharp & Dohme LLC
-
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- UPMC Hillman Cancer Center-UPMC ( Site 6904), Pittsburgh, Pennsylvania
- Locations
- 50 in total
- Run by
- Merck Sharp & Dohme LLC
-
Distance-Based Exercise to Preserve Function and Prevent Disability
This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength. These side e…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
- Locations
- 18 in total
- Run by
- Alliance for Clinical Trials in Oncology
-
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
- Stage
- Phase 1
- Ages
- 18 to 90
- Site
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
- Locations
- 11 in total
- Run by
- Perspective Therapeutics
-
Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)
The goal of this study is to determine the feasibility of a prehabilitation exercise and nutrition program (exercise and nutrition before a medical treatment) in adults with esophageal cancer before surgery (esophagectomy). The pre-surgery exercise and nutrition program will include resistance and …
- Stage
- Not phased
- Ages
- 18 and older
- Site
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
- Run by
- University of Pittsburgh
-
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
- Run by
- Diwakar Davar
-
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
To assess short and long term outcomes after minimally invasive esophagectomy compared to open esophagectomy. To compare both standard outcome measures as well as patient derived outcome measures, in particular, quality of life (QOL). To look at the applicability of this QOL instrument to this pati…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- University of Pittsburgh Medical Center - Department of Cardiothoracic Surgery, Pittsburgh, Pennsylvania
- Locations
- 2 in total
- Run by
- University of Pittsburgh
-
Esophageal Cancer Risk Registry
The purpose of this study is to identify markers in the blood and tissue that could indicate risk factors for the development and progression of esophagus cancer. This research aims to collect medical history, blood, and tissue samples from patients who present with an esophageal disorder. Identify…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Department of Cardiothoracic Surgery, Pittsburgh, Pennsylvania
- Run by
- University of Pittsburgh
-
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpos…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Allegheny Health Network, Pittsburgh, Pennsylvania
- Locations
- 18 in total
- Run by
- UMC Utrecht
-
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
This research study aims to evaluate the safety and determine the optimal dose of a new experimental drug, vvDD-hIL2 (vaccinia virus double-deleted human interleukin 2), in patients with advanced abdominal cancer. The study will involve three dose levels, with three to six patients enrolled at each…
- Stage
- Phase 1
- Ages
- 18 to 69
- Site
- AHN West Penn Hospital, Pittsburgh, Pennsylvania
- Run by
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.